Enhanced morphine analgesia in mice lacking beta-arrestin 2
about
β-arrestin Kurtz inhibits MAPK and Toll signalling in Drosophila developmentEndothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivoSensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- miceHerkinorin analogues with differential beta-arrestin-2 interactionsbeta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in miceImprovement of morphine-mediated analgesia by inhibition of β-arrestin2 expression in mice periaqueductal gray matterStructure-based discovery of opioid analgesics with reduced side effects.Opioid-induced constipation: advances and clinical guidanceThe emerging roles of β-arrestins in fibrotic diseasesMultifaceted role of β-arrestins in inflammation and diseaseThe mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependenceTargeting G protein coupled receptor-related pathways as emerging molecular therapiesOpioid receptor heteromers in analgesiaThe physiological relevance of functional selectivity in dopamine signallingPositive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medicationsRecruitment of β-Arrestin into Neuronal Cilia Modulates Somatostatin Receptor Subtype 3 Ciliary Localization.Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Current research on opioid receptor function.A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental healthDynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexesbeta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and traffickingMultiple actions of spinophilin regulate mu opioid receptor functionActivation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talkCombinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung CancerReceptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimersBiased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonistsβ-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel.Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia.Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the EndorphinsRegulation of amygdalar PKA by beta-arrestin-2/phosphodiesterase-4 complex is critical for fear conditioningA beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers.β-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain.Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation.The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulationbeta-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.
P2860
Q24297887-60A3E25E-964C-42A2-9783-3FD1C02A358AQ24323818-946A3CE8-F1EF-48EE-BA9F-830F06FDD8EDQ24646270-32F46C8A-F85A-48D5-906F-5B1C74431DF5Q24647416-894B1A08-4DA2-447B-8657-E3788C936739Q24647599-2E065F6A-11BB-4394-98AF-247D97345193Q24649793-F159691A-FCE5-4950-B520-B9EF8C28ECCBQ24654027-7C12044A-88A5-4191-BE26-2E81D99121C9Q24656000-D9C0FD06-4005-4B53-8B97-4BAA56D23193Q26331003-EBD9BE68-15E4-4A16-90A5-D2BB0820F01FQ26765571-BC90271C-D356-4D67-98D2-A8EFDAF33EF6Q26783047-3BF9F61C-F7A8-4C92-90E8-AB57234F0483Q26785883-81328CB9-F477-458E-B632-339B53A0E6BDQ26801420-5EF43EB5-7812-4063-A0AF-6990FFE90A78Q26829964-1B6C2EAB-929B-4C9E-B7F5-794850C75E8AQ27004306-D6A0904F-5418-45EA-A307-E1D09381A693Q27027511-1C755395-CC01-47F2-8CAB-17D6874EC309Q27027736-17831FA8-D0D8-4019-968C-11B75FDEAB3BQ27320734-9162A366-897B-49AA-992F-2A68FBF49782Q27324174-3B596773-9E3C-43A2-B15E-D946E1A5822FQ27693220-3EDFA18E-633D-4567-97F3-85E9594EF3CAQ28118906-263CFCF4-F023-4294-A774-C452B1AB1AB8Q28263696-A6928981-596C-45C6-ADC8-02D52564EF7FQ28507206-01E641C8-0BFE-4931-B393-E6F663246F3AQ28512764-6D1A6A8F-ACCB-40A2-95AC-1005D6C5EDD1Q28541771-41D018D2-5930-4A28-88FF-3B181DBC84B4Q28547364-79A6ACAA-E7AE-448F-8A06-AED0ED3A16C2Q28584024-E20BEF57-9AA8-43A3-A86C-5E8708E8BE93Q30359656-E899BB13-2BC8-4E52-9E78-E9496F06896BQ30448011-C92860A3-615E-47B8-850D-A234C22414EBQ30470945-94674090-144A-42BA-838A-EDBA60900FA9Q30841944-6EDF315E-5659-46FE-AA0B-4DF005C11A05Q33564436-6C95BD6D-19B8-4071-BAB6-697B9CA86A38Q33779634-61EBCB49-F5DE-44BB-B27E-080AE52688E7Q33805049-566B43AB-F15C-4026-8C9F-F575814BF78EQ33814944-7606A61C-D00F-47AE-86B2-430B98B0C838Q33815047-20A2D6CC-D04B-472F-8209-3F1A256E5EB5Q33840022-3C5BF080-C102-4247-935C-8BEEAB64F8DCQ33841893-9E80477E-DB1D-496D-9B92-2E3FC9791D99Q33863494-FEB6A0BB-3036-4E53-8E85-9B43B3201375Q33890786-7957D9FC-A07B-4260-9050-E69E96668407
P2860
Enhanced morphine analgesia in mice lacking beta-arrestin 2
description
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Science
@fr
artículu científicu espublizáu en 1999
@ast
im Dezember 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/12/24)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/12/24)
@nl
наукова стаття, опублікована в грудні 1999
@uk
name
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@ast
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@en
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@nl
type
label
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@ast
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@en
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@nl
prefLabel
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@ast
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@en
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@nl
P2093
P1433
P1476
Enhanced morphine analgesia in mice lacking beta-arrestin 2
@en
P2093
L. M. Bohn
M. G. Caron
R. J. Lefkowitz
R. R. Gainetdinov
P304
P407
P577
1999-12-24T00:00:00Z